Non-invasive neurostimulation given to people with mild-to-moderate Alzheimer’s disease significantly and safely slowed their rate of functional and cognitive decline, meeting key goals of the Phase 2 OVERTURE study, according to data presented at the 2021 AD/PD Conference. Its neurostimulation device, being referred to as a digital therapeutic, uses gamma frequency technology for neuromodulation. With this system, a patient’s brainwave patterns are analyzed to design an individualized sequence of visual or auditory signals meant to provoke certain therapeutic…
You must be logged in to read/download the full post.
The post Neurostimulation Slows Decline in Mild-to-moderate Alzheimer’s, Trial Finds appeared first on BioNewsFeeds.